EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Epilepsy Drug Pipeline: Update on Near-to-Market Therapies

Christopher Elder iD, Jacob Pellinen iD, Samuel W Terman iD

Seminars in Neurology · 01.04.2025 · 45 (02) · 287-297

DOI: 10.1055/a-2580-1187 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Neurology, erschienen am 01.04.2025. Verfasst von Christopher Elder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, NYU Grossman School of Medicine and NYU Langone Health, New York, New York. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Drug Development. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the first antiseizure medication (ASM) was introduced in 1857, more than 30 medications have been approved by the United States Food and Drug Administration (FDA) for the treatment of epilepsy. However, limitations in efficacy and tolerability have led to one-third of patients suffering from uncontrolled seizures. Recent advances in genetics, disease modeling, high-throughput target-based and phenotype-based screening, study design, and identification of novel mechanisms of action or routes of delivery have resulted in more than 200 therapeutics currently under development in the epilepsy pipeline. This study discusses near-to-market drugs in advanced clinical development, with select drugs in earlier stages. Background regarding mechanisms, animal studies, pharmacokinetics, pharmacodynamics, efficacy, tolerability, and safety data are provided for each drug when available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsyDrug DevelopmentHumansAnimalsDrug ApprovalUnited StatesUnited States Food and Drug Administration

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Department of Neurology, NYU Grossman School of Medicine and NYU Langone Health, New York, New York.
  • Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado.
  • Department of Neurology, University of Michigan, Ann Arbor, Michigan.

ORCID-Profile: Christopher Elder, Jacob Pellinen, Samuel W Terman

Zitieren

APA

Elder, C., Pellinen, J., & Terman, S. W. (2025). The Epilepsy Drug Pipeline: Update on Near-to-Market Therapies. Seminars in Neurology, 45(02), 287-297. https://doi.org/10.1055/a-2580-1187

Vancouver

Elder C, Pellinen J, Terman SW. The Epilepsy Drug Pipeline: Update on Near-to-Market Therapies. Seminars in Neurology. 2025;45(02):287-297. doi:10.1055/a-2580-1187

BibTeX
@article{Elder2025,
  author = {Elder, Christopher and Pellinen, Jacob and Terman, Samuel W},
  title = {The Epilepsy Drug Pipeline: Update on Near-to-Market Therapies},
  journal = {Seminars in Neurology},
  year = {2025},
  volume = {45},
  number = {02},
  pages = {287--297},
  doi = {10.1055/a-2580-1187}
}
Kostenlos starten →